SMARCA2 and Miyoshi myopathy: Our in vivo assessments with the first-in-class orally bioavailable SMARCA2/4 PROTAC degrader, AU-24118, demonstrated a favorable tolerability profile alongside significant anti-tumor efficacy in multiple SCLC-P and MM preclinical models.